INDRAYANI BIOTECH LTD. (INDRANIB) Fair Value & Analysis

Industrials · IN · Market cap ₹388M

Below-average quality, currently priced close to our fair value.

What matters now

• The price sits close to our fair value, market and models broadly agree here, little valuation tension.
• A fairly wide model range (₹5.40 to ₹10.79) leaves room in how you read the outcome.
• Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range ₹4.86 – ₹112.25 · fair‑value band ₹5.40 – ₹10.79 · the ₹7.50 price screens above the ₹7.23 fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

INDRAYANI BIOTECH LTD. (INDRANIB) currently trades at ₹7.50, while our model-based Fair Value estimate is ₹7.23, implying the stock looks roughly 3.6% fairly valued today. The Quality Score stands at 18/100 (below-average quality), in the Industrials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Over the trailing twelve months, INDRAYANI BIOTECH LTD. generated revenue of ₹1.5B at a net margin of -1.9%. Revenue grew 102.2% year over year. It earns a return on equity of -6.9%. Net debt stands at ₹1.4B. Fundamentals as of Aug 13, 2026

Our scenario range runs from ₹5.40 (bear case) to ₹10.79 (bull case); at ₹7.50, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 55% below its 52-week high and 23% above its 52-week low, currently below its 200-day average. For context, the median of 10 Industrials peers we cover trades at -22% fair-value upside, at -4%, INDRANIB screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Asset-Based (₹10.67) versus Multiples (₹0.7100). Highest evidence: EV/EBITDA (54).

Key figures & financial health

Quality Score breakdown

About the company

Indrayani Biotech Limited, together with its subsidiaries, engages in the engineering, food and hospitality, dairy, healthcare and pharma, engineering, infrastructure, agriculture, and biotech businesses. It operates food court chains under the Nalla Sappadu brand; offers catering services; and food supply services.

Full company description

Indrayani Biotech Limited, together with its subsidiaries, engages in the engineering, food and hospitality, dairy, healthcare and pharma, engineering, infrastructure, agriculture, and biotech businesses. It operates food court chains under the Nalla Sappadu brand; offers catering services; and food supply services. It also designs, develops, manufactures, and maintains, and services power electronics. Its products include FCBC, battery chargers, modulars, industrial and commercial on-line UPS systems, industrial inverters, AC/DC power supplies, DC-DC converters, servo-controlled voltage stabilizers, automatic rescue devices, and special purpose machines. In addition, it markets and sells microorganisms based bio fertilizers, bio pest controllers, bio fortified vermi compost and bio fortified coirpoth, as well as pseudomonas, beauveria bassiana, metarhizium, potash mobiliser, tricoderma viride, verticillium lecanii, humic acid, bio fortified coirpith compost, bio fortified vermicompost, MN mixture, NP virus, and VAM to farmers; and manufactures milk protein-based products, such as skimmed milk powder, milk protein concentrates, milk whey powder, whey powder and protein concentrates, evaporated milk, whole milk powder, dairy whitener, and casein protein under the EnNutrica brand. Further, it operates IBL Eyecare clinic at Tiruvannamalai, Nalam Multispeciality Dental Clinic at Chennai, and Lafuse Hair and Skin Clinic at Chennai; manufactures waste heat recovery systems package boilers, economisers, super heaters, steam drums, deaerator cum feed water storage tankers, blow down systems, dosing systems, heat exchangers, pressure vessels and storage tanks, water-preheaters, and air-preheaters under the IBL MATRIX brand; and produces organic vegetables, fruits, and other grocery industries and other establishments, as well as develops commercial and residential infrastructure projects. The company was incorporated in 1992 and is based in Chennai, India.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

INDRAYANI BIOTECH LTD. reported revenue of ₹1.3B in FY2025 versus ₹211M in FY2021, a compound +57.6%/yr. Reported net income was −₹61.1M in FY2025.

Watch INDRANIB: get an alert when its fair value changes →

Peer Group

Specialty Business Services · 252 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Specialty Business Services median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Specialty Business Services stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Explore undervalued stocks

More undervalued Industrials stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.